Literature DB >> 18768986

Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis.

Christina L Gardner1, Crystal W Burke, Mulu Z Tesfay, Pamela J Glass, William B Klimstra, Kate D Ryman.   

Abstract

Eastern and Venezuelan equine encephalitis viruses (EEEV and VEEV, respectively) cause severe morbidity and mortality in equines and humans. Like other mosquito-borne viruses, VEEV infects dendritic cells (DCs) and macrophages in lymphoid tissues, fueling a serum viremia and facilitating neuroinvasion. In contrast, EEEV replicates poorly in lymphoid tissues, preferentially infecting osteoblasts. Here, we demonstrate that infectivity of EEEV for myeloid lineage cells including DCs and macrophages was dramatically reduced compared to that of VEEV, whereas both viruses replicated efficiently in mesenchymal lineage cells such as osteoblasts and fibroblasts. We determined that EEEV infection of myeloid lineage cells was restricted after attachment, entry, and uncoating of the genome. Using replicon particles and translation reporter RNAs, we found that translation of incoming EEEV genomes was almost completely inhibited in myeloid, but not mesenchymal, lineage cells. Alpha/beta interferon (IFN-alpha/beta) responses did not mediate the restriction, as infectivity was not restored in the absence of double-stranded RNA-dependent protein kinase, RNase L, or IFN-alpha/beta receptor-mediated signaling. We confirmed these observations in vivo, demonstrating that EEEV is compromised in its ability to replicate within lymphoid tissues, whereas VEEV does so efficiently. The altered tropism of EEEV correlated with an almost complete avoidance of serum IFN-alpha/beta induction in vivo, which may allow EEEV to evade the host's innate immune responses and thereby enhance neurovirulence. Taken together, our data indicate that inhibition of genome translation restricts EEEV infectivity for myeloid but not mesenchymal lineage cells in vitro and in vivo. In this regard, the tropisms of EEEV and VEEV differ dramatically, likely contributing to observed differences in disease etiology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768986      PMCID: PMC2573165          DOI: 10.1128/JVI.01323-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Calculating nucleic acid secondary structure.

Authors:  M Zuker
Journal:  Curr Opin Struct Biol       Date:  2000-06       Impact factor: 6.809

2.  Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism.

Authors:  K D Ryman; W B Klimstra; K B Nguyen; C A Biron; R E Johnston
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  A single-site mutant and revertants arising in vivo define early steps in the pathogenesis of Venezuelan equine encephalitis virus.

Authors:  J F Aronson; F B Grieder; N L Davis; P C Charles; T Knott; K Brown; R E Johnston
Journal:  Virology       Date:  2000-04-25       Impact factor: 3.616

4.  Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis.

Authors:  G H MacDonald; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Structural and nonstructural protein genome regions of eastern equine encephalitis virus are determinants of interferon sensitivity and murine virulence.

Authors:  Patricia V Aguilar; A Paige Adams; Eryu Wang; Wenli Kang; Anne-Sophie Carrara; Michael Anishchenko; Ilya Frolov; Scott C Weaver
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

6.  Alpha/beta interferon inhibits cap-dependent translation of viral but not cellular mRNA by a PKR-independent mechanism.

Authors:  Mulu Z Tesfay; Jun Yin; Christina L Gardner; Mikhail V Khoretonenko; Nadejda L Korneeva; Robert E Rhoads; Kate D Ryman; William B Klimstra
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

7.  Translational control of the innate immune response through IRF-7.

Authors:  Rodney Colina; Mauro Costa-Mattioli; Ryan J O Dowling; Maritza Jaramillo; Lee-Hwa Tai; Caroline J Breitbach; Yvan Martineau; Ola Larsson; Liwei Rong; Yuri V Svitkin; Andrew P Makrigiannis; John C Bell; Nahum Sonenberg
Journal:  Nature       Date:  2008-02-13       Impact factor: 49.962

8.  Analysis of Venezuelan equine encephalitis virus capsid protein function in the inhibition of cellular transcription.

Authors:  Natalia Garmashova; Svetlana Atasheva; Wenli Kang; Scott C Weaver; Elena Frolova; Ilya Frolov
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

9.  A five-amino-acid deletion of the eastern equine encephalitis virus capsid protein attenuates replication in mammalian systems but not in mosquito cells.

Authors:  Patricia V Aguilar; Lawrence W Leung; Eryu Wang; Scott C Weaver; Christopher F Basler
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Identification and characterization of interferon-induced proteins that inhibit alphavirus replication.

Authors:  Yugen Zhang; Crystal W Burke; Kate D Ryman; William B Klimstra
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

View more
  59 in total

Review 1.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

2.  Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate.

Authors:  Christina L Gardner; Crystal W Burke; Stephen T Higgs; William B Klimstra; Kate D Ryman
Journal:  Virology       Date:  2012-02-01       Impact factor: 3.616

3.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

4.  Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.

Authors:  Daniel R Tonkin; Alan Whitmore; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2012-04-21       Impact factor: 3.641

5.  Closing the gap between viral and noninfectious arthritis.

Authors:  Kate D Ryman; William B Klimstra
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

6.  Electroporation of Alphavirus RNA Translational Reporters into Fibroblastic and Myeloid Cells as a Tool to Study the Innate Immune System.

Authors:  Christina L Gardner; Derek W Trobaugh; Kate D Ryman; William B Klimstra
Journal:  Methods Mol Biol       Date:  2016

7.  Type I IFN controls chikungunya virus via its action on nonhematopoietic cells.

Authors:  Clémentine Schilte; Thérèse Couderc; Fabrice Chretien; Marion Sourisseau; Nicolas Gangneux; Florence Guivel-Benhassine; Anton Kraxner; Jürg Tschopp; Stephen Higgs; Alain Michault; Fernando Arenzana-Seisdedos; Marco Colonna; Lucie Peduto; Olivier Schwartz; Marc Lecuit; Matthew L Albert
Journal:  J Exp Med       Date:  2010-02-01       Impact factor: 14.307

8.  A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus.

Authors:  Chad J Roy; A Paige Adams; Eryu Wang; Grace Leal; Robert L Seymour; Satheesh K Sivasubramani; William Mega; Ilya Frolov; Peter J Didier; Scott C Weaver
Journal:  Vaccine       Date:  2013-01-16       Impact factor: 3.641

9.  Characteristics of alpha/beta interferon induction after infection of murine fibroblasts with wild-type and mutant alphaviruses.

Authors:  Crystal W Burke; Christina L Gardner; Joshua J Steffan; Kate D Ryman; William B Klimstra
Journal:  Virology       Date:  2009-09-25       Impact factor: 3.616

10.  A mouse model for studying viscerotropic disease caused by yellow fever virus infection.

Authors:  Kathryn C Meier; Christina L Gardner; Mikhail V Khoretonenko; William B Klimstra; Kate D Ryman
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.